Previous 10 | Next 10 |
Phase 1b Clinical Trial, heart-1, Now Underway and Enrolling Patients with Heterozygous Familial Hypercholesterolemia in New Zealand Company Executing VERVE-101 Global Regulatory Strategy with Potential Clearances for a UK Clinical Trial Application and US Investigational New Dr...
The recent 4-year partnership between Pfizer and Beam Therapeutics involves $300 million upfront to speed validation of the technology and an additional $1.05 billion in milestone payments. A recent amended agreement between Verve Therapeutics and Beam Therapeutics is a target swap th...
The most heavily shorted names have been rallying off their lows in the past several days. On a relative basis, the 100 most heavily shorted stocks versus the Russell 3,000 have broken out of the downtrend that has been in place since the height of the meme stock mania in January 2021...
Clinical-stage biotech Graphite Bio (NASDAQ:GRPH) traded sharply higher on Friday after BMO Capital Markets initiated its coverage with an Outperform rating and a $12 per share target implying a premium of ~461% to the last close. The analyst Kostas Biliouris highlights the company’s g...
The shares of Legend Biotech (LEGN) and Verve Therapeutics (NASDAQ:VERV) are on the rise in the morning hours Friday after BMO Capital Markets initiated their coverage, categorizing the biotech firms as its top picks. As reasons for the classification, the analyst Kostas Biliouris highlights ...
CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. “Bo” Cumbo, chief executive officer...
A group of biotechs focused on gene therapy candidates surged on Tuesday after the FDA posted a favorable review on a β-thalassemia candidate developed by commercial-stage company Bluebird bio (NASDAQ:BLUE) ahead of an AdCom meeting later this week. The data for the marketing applicati...
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer...
The following slide deck was published by Verve Therapeutics, Inc. in conjunction with this event. For further details see: Verve Therapeutics (VERV) Presents at the TIDES USA Annual Event - Slideshow
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory Filings for VERVE-101 in Second Half of 2022 Cash, Cash...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...